NIAID Cancels HIV Vaccine Trial

Armen Hareyan's picture

NIAID canceled HIV vaccine trial because there is still not enough information about how human immune system will accept the vaccine against HIV.

National Institute of Allergy and Infectious Diseases was conducting this trial, which was unique with its way stimulating immune system to fight infection. There are some other HIV related trials as well, but scientists were hoping that the governmental one will succeed.

Twenty four years ago scientists started working on HIV vaccine development, and government promised to have a licensed vaccine by 1987, but still there is no successful vaccine, which could prevent HIV infection and stop AIDS development.


Partnership for AIDS Vaccine Evaluation (PAVE 100) is the name of HIV vaccine trial by NIAID, which is decided to be stopped. NIAID officials announced that there is need in examining immune system and the infection, in conducting more animal studies before trying the vaccine on humans.

This vaccine was very similar to the one by Merck, which was terminated last year. When Dr. Anthony S. Fauci, director of the National Institute of Allergy and Infectious Diseases, met with scientists to discuss and to understand why exactly Merck’s HIV vaccine trial failed, it became clear that it is too early for NIAID to conduct a human trial.

Scientists now need to understand which immune reactions need to be targeted to prevent the infection. They also need to prove that the vaccine is able to lower the amount of HIV in blood of infected patients.

Dr. Fauci decided that as soon as scientists show that the new HIV vaccine lowers the amount of HIV in blood in a small human trial, NIAID will go to a larger human trial. Until then, scientists need to work hard to show that the vaccine is worth to participate in a large trial.